Delcath Systems Inc (DCTH) said after close Monday that it lost $1.14 per share in quarter three 2023.
On the revenue line, the company reported $434 thousand, missing estimates by $246 thousand.
In the same quarter a year ago, the company lost $0.92 per share on revenue of $906 thousand.
The stock is down 15.10% to $2.53 after the report.
Despite Delcath Systems Inc reporting a decline in revenues, earnings increased signaling a rise in profit margins.
The average recommendation from Wall Street analysts was a Strong Buy which may get revised based on this new data.
InvestorsObserver gives the stock a Neutral Sentiment score at the moment based on recent trading.
Prior to the report, InvestorsObserver gave the stock an overall score of 0. Meanwhile, the average Wall Street analyst rated the stock a Strong Buy.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product candidate, Melphalan Hydrochloride for Injection for use with the Delcath Hepatic Delivery System, or Melphalan/HDS, is designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects.
News Home
Delcath Systems Inc Down 15.10% To $2.53 After Earnings Miss
Mentioned in this article
